Adaptive Biotechnologies (NASDAQ:ADPT) Insider Francis Lo Sells 22,564 Shares

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) insider Francis Lo sold 22,564 shares of the business’s stock in a transaction dated Wednesday, April 8th. The shares were sold at an average price of $15.07, for a total value of $340,039.48. Following the transaction, the insider owned 271,154 shares in the company, valued at $4,086,290.78. This represents a 7.68% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Francis Lo also recently made the following trade(s):

• On Wednesday, March 11th, Francis Lo sold 30,593 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $14.08, for a total value of $430,749.44.
• On Thursday, March 5th, Francis Lo sold 38,074 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $15.09, for a total value of $574,536.66.
• On Monday, January 12th, Francis Lo sold 79,590 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $17.73, for a total value of $1,411,130.70.

Adaptive Biotechnologies Trading Down 4.6%

ADPT traded down $0.61 on Friday, hitting $12.79. 3,310,057 shares of the stock traded hands, compared to its average volume of 2,060,273. Adaptive Biotechnologies Corporation has a 52 week low of $6.77 and a 52 week high of $20.76. The firm has a market capitalization of $1.97 billion, a PE ratio of -31.97 and a beta of 2.29. The business has a fifty day moving average price of $15.07 and a two-hundred day moving average price of $15.96.

Adaptive Biotechnologies (NASDAQ:ADPT) last issued its quarterly earnings results on Thursday, February 5th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.19) by $0.10. Adaptive Biotechnologies had a negative return on equity of 46.68% and a negative net margin of 21.48%.The firm had revenue of $71.68 million for the quarter, compared to analyst estimates of $59.38 million. During the same period in the previous year, the company posted ($0.23) earnings per share. The company’s quarterly revenue was up 51.0% compared to the same quarter last year. On average, equities research analysts forecast that Adaptive Biotechnologies Corporation will post -0.92 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on the company. Piper Sandler set a $21.00 price target on Adaptive Biotechnologies in a research note on Friday, February 6th. Wall Street Zen cut Adaptive Biotechnologies from a “buy” rating to a “hold” rating in a report on Saturday, March 7th. TD Cowen restated a “buy” rating on shares of Adaptive Biotechnologies in a research report on Friday, February 6th. Guggenheim boosted their price target on Adaptive Biotechnologies from $20.00 to $21.00 and gave the company a “buy” rating in a research note on Monday, January 26th. Finally, JPMorgan Chase & Co. upped their price target on Adaptive Biotechnologies from $20.00 to $21.00 and gave the company an “overweight” rating in a research report on Friday, February 6th. Seven equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Adaptive Biotechnologies presently has an average rating of “Moderate Buy” and a consensus target price of $18.25.

Hedge Funds Weigh In On Adaptive Biotechnologies

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Caitong International Asset Management Co. Ltd acquired a new stake in shares of Adaptive Biotechnologies during the fourth quarter worth approximately $28,000. Sound Income Strategies LLC bought a new position in shares of Adaptive Biotechnologies in the third quarter valued at approximately $30,000. EverSource Wealth Advisors LLC boosted its holdings in shares of Adaptive Biotechnologies by 197.1% in the 4th quarter. EverSource Wealth Advisors LLC now owns 2,359 shares of the company’s stock worth $38,000 after acquiring an additional 1,565 shares in the last quarter. Assetmark Inc. boosted its holdings in shares of Adaptive Biotechnologies by 867.9% in the 4th quarter. Assetmark Inc. now owns 3,020 shares of the company’s stock worth $49,000 after acquiring an additional 2,708 shares in the last quarter. Finally, T. Rowe Price Investment Management Inc. bought a new stake in Adaptive Biotechnologies during the 4th quarter worth approximately $51,000. 99.17% of the stock is currently owned by institutional investors and hedge funds.

About Adaptive Biotechnologies

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.